ADVA sync solution enables major Chilean telco to roll out 5G-ready network
28.10.2019 15:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that its Oscilloquartz synchronization technology is enabling one of Chile’s largest communication service providers (CSPs) to roll out LTE Advanced (LTE-A) connectivity across the country and prepare for 5G. The OSA 5430 Series and OSA 5410 Series of PTP grandmaster clocks and GNSS receivers deliver stringent phase synchronization in the core and in the access network, enabling the company to address rapidly rising customer demand for premium services such as high-definition video streaming. The deployment strengthens ADVA’s position in the market with its timing technology now synchronizing more of Chile’s major CSP networks than any other supplier’s solutions. The network is being installed by ADVA’s long-term partner Sistemas de Instrumentación Ltda.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191028005386/en/
The OSA 5430 Series and OSA 5410 Series are enabling one of Chile’s largest CSPs to roll out national LTE-A connectivity (Photo: Business Wire)
“Being selected to transform the sync network of another of Chile’s key CSPs highlights the unique benefits of our grandmaster clocks and GNSS receiver portfolio. With high-quality oscillators guaranteeing unbeatable holdover and the continual assurance of in-service sync with our built-in probes, our technology offers the most complete and comprehensive solution for advanced timing in telecom networks. It will generate value for years to come,” said Gil Biran, general manager, Oscilloquartz. “Our mission is to provide exceptional service to all of our customers. With our technology and ongoing support, we’re empowering another major company to reshape Chile’s telecommunication landscape, reaching more people than ever while continuing to deliver unrivalled quality of service.”
By deploying the small yet versatile OSA 5410 Series in the access networks, the CSP is providing advanced, time-sensitive mobile connectivity throughout Chile, including previously underserved regions. At once a mini-grandmaster, boundary clock, slave device and sync probe, ADVA’s multipurpose devices lead the industry in terms of adaptability and innovation. At its core, the company is utilizing the OSA 5430 Series, which offers full hardware redundancy, significantly reducing downtime. This high-capacity unit also provides unprecedented scale, supporting speeds of up to 10Gbit/s. Additionally, the OSA 5410 and 5430 both support assisted partial timing support (APTS) and feature Oscilloquartz’s best-in-class oven-controlled crystal oscillators, which offer exceptional holdover performance even in the most challenging conditions.
"We work closely with our partner ADVA to deliver world-class technology that ensures unbeatable quality and availability. Their Oscilloquartz grandmasters are the most advanced timing solutions on the market. Ideal for distributing ultra-precise, incredibly reliable phase and time-of-day information, these devices are now providing the heartbeat of another of Chile’s leading CSPs,” commented Danor Quinteros, CEO, Sistemas de Instrumentación Ltda. “One of the crucial elements of this deployment was bringing synchronization close to the end user where it’s most needed. The compact and feature-rich OSA 5410 devices in the access network and the high-capacity OSA 5430 in the core infrastructure will be key to delivering ever-faster speeds and latency-sensitive applications.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to- end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA Optical Networking company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at: www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005386/en/
Contact information
For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
